A Phase Ia, Multicenter, Open-Label, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Lampalizumab (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions
- Sponsors Genentech
- 04 Dec 2013 New trial record